Core Viewpoint - The proposed equity transfer of 5.05% stake in Ruikang Pharmaceutical by controlling shareholder Zhang Renhua to Yanquan No. 8 private equity fund has been terminated after nine months due to "significant changes in the objective environment," despite an initial transaction value of 162 million yuan [1][2]. Group 1: Transaction Details - The transaction was initially valued at 162 million yuan, with an unusually lenient payment structure: only 5 million yuan (3.1%) was required as the first payment, followed by 50 million yuan within 15 working days after the transfer, and the remaining 106.9 million yuan allowed to be deferred for 90 days [2]. - The Yanquan Wealth management scale was less than 500 million yuan, with all seven operating funds marked as having a "surviving scale of less than 10 million yuan," indicating a significant funding gap for the transaction [3]. Group 2: Obstacles to Completion - Three main obstacles were identified that typically lead to the failure of such agreements: fundraising difficulties, potential undisclosed issues with the equity, and speculative market behavior [4]. - The mismatch between the capital strength of Yanquan Fund and the scale of the transaction was a substantial barrier to completion [4]. Group 3: Market Context - The termination of this agreement is part of a broader trend, with over ten A-share companies announcing similar terminations in May 2025 alone, surpassing the total from the previous four months and accounting for 25% of such cases in 2023 [5]. - The ongoing weak market environment has made it increasingly difficult for buyers to raise funds, particularly for large equity transfers of companies trading below net asset value [5]. Group 4: Shareholder Dynamics - The background of this transfer reflects the difficulties faced by controlling shareholders, as Ruikang Pharmaceutical's stock price has been persistently below net asset value since 2023, limiting their ability to reduce holdings in the secondary market [6]. - The failed transaction was initially seen as a potential solution to the shareholder's predicament, but the design flaws in the transaction ultimately led to its collapse [6].

瑞康医药集团股份有限公司 上市公司名称:瑞康医药集团股份有限公司 股票简称：瑞康医药 股票代码：002589 股票上市地点:深圳证券交易所 信息披露义务人：荆州招商慧泽医药投资合伙企业（有限合伙） 住所或通讯地址：荆州经济技术开发区管委会1号楼招商中心一楼 股份变动性质：股份减少，持股比例降至5%以下 签署日期：2025年6月3日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、 《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相关 的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司以下简称"瑞康医 药"）中拥有权益的股份变动情况；截止本报告书签署之日，除本报告书披露的持股 信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在瑞康医药拥有 权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的；除信息披露义务人外， 没有委托或授权任何其他人提供未在本报告书中列载的信息和 ...

瑞康医药集团股份有限公司 简式权益变动报告书 上市公司名称:瑞康医药集团股份有限公司 股票简称：瑞康医药 股票代码：002589 股票上市地点:深圳证券交易所 信息披露义务人：荆州招商慧泽医药投资合伙企业（有限合伙） 住所或通讯地址：荆州经济技术开发区管委会1号楼招商中心一楼 股份变动性质：股份减少，持股比例降至5%以下 签署日期：2025年6月3日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相关 的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司以下简称"瑞康医 药"）中拥有权益的股份变动情况；截止本报告书签署之日，除本报告书披露的持股 信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在瑞康医药拥有 权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的；除信息披露义务人外， 没有委托或授权任何其他人提供未在本报 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-033 瑞康医药集团股份有限公司 关于控股股东终止协议转让公司部分股份的公告 控股股东张仁华女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 瑞康医药集团股份有限公司（以下简称"公司"）于近日收到股东张仁华女士 通知，获悉张仁华女士与岩泉8号私募证券投资基金（以下简称"岩泉8号基金"） 就终止协议转让公司部分股份事宜达成一致意见，并签署了《股份转让协议之补 充协议（二）》。现将相关事宜公告如下： 一、协议转让事项概述 2024年8月1日，公司股东张仁华女士与岩泉8号基金签署了《股份转让协议》， 张仁华女士拟通过协议转让方式将其持有的76,000,000股公司股份（占公司总股 本的5.05%）转让给岩泉8号基金，转让价格为2.13元/股，股份转让总价款为人民 币161,880,000元。 根据《中华人民共和国证券法》《上市公司收购管理办法》等相关法律法规 的要求，相关信息披露义务人已就本次股份协议转让事宜履行了信息披露义务， 具体内容详见公司2 ...

Core Viewpoint - The legal opinion confirms that the 2024 Annual General Meeting of Ruikang Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][11]. Group 1: Meeting Procedures - The meeting was convened based on resolutions from the 14th and 16th meetings of the fifth board of directors held on April 23 and May 6, 2025, respectively [2]. - The notice for the meeting and a supplementary notice were published on April 24 and May 7, 2025, in various financial newspapers and on the official website [2][3]. Group 2: Attendance and Qualifications - The equity registration date for the meeting was May 9, 2025, with a total of 1 shareholder present, representing 185,491,897 shares, which is 12.3274% of the total voting shares [3][4]. - Additionally, 300 shareholders participated via online voting, representing 11,644,879 shares, or 0.7739% of the total voting shares [4]. Group 3: Agenda Items - The agenda included the following items: 1. 2024 Annual Report and its summary 2. 2024 Board of Directors' Work Report 3. 2024 Financial Settlement Report 4. 2024 Supervisory Board Work Report 5. Proposal for the board to issue shares to specific targets via simplified procedures, which requires a special resolution [4][5]. Group 4: Voting Process and Results - The voting was conducted through a combination of on-site written voting and online voting, adhering to legal and regulatory requirements [5][11]. - The voting results showed that 190,902,607 shares (96.8376%) were in favor, 4,593,560 shares (2.3301%) opposed, and 1,640,609 shares (0.8322%) abstained [6][9]. - For minority investors, 5,410,710 shares (46.4643%) were in favor, while 4,593,560 shares (39.4470%) opposed, and 1,640,609 shares (14.0887%) abstained [6][8]. Group 5: Conclusion - The legal opinion concludes that the meeting's procedures, attendance qualifications, and voting processes complied with the Company Law and relevant regulations, affirming the validity of the resolutions passed [11][12].

瑞康医药集团股份有限公司 2024 年年度股东大会决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 一、 重要提示 1、本次股东大会未涉及变更以往股东大会已通过的决议。 2、本次股东大会召开期间没有增加、否决或变更议案的情况发生。 证券代码：002589 证券简称：瑞康医药 公告编号：2025-032 二、 会议通知情况 《瑞康医药集团股份有限公司关于召开 2024 年年度股东大会的通知》、《关 于增加 2024 年年度股东大会临时提案的补充通知》于 2025 年 4 月 24 日、2025 年 5 月 7 日在《证券时报》、《中国证券报》、《证券日报》、《上海证券报》 和巨潮资讯网上已经披露。 三、 会议召开基本情况 1、会议召集人：公司董事会 2、会议时间：2025 年 5 月 16 日（星期五）下午 15:00 3、会议召开地点：山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 4、会议主持人：董事长韩旭先生 5、会议召开方式：现场会议结合网络投票方式 6、 本次会议的召集、召开符合《公司法》、《上市公司股东大会规则》、 《深圳证券交易所 ...

山东乾元律师事务所·法律意见书 关于瑞康医药集团股份有限公司 2024 年年度股东大会的律师见证法律意见书 致：瑞康医药集团股份有限公司 山东乾元律师事务所（以下简称"本所"）接受贵公司的委托，指派衣 超律师、袁伟芳律师（以下简称"本所律师"）出席贵公司于 2025 年 5 月 16 日下午 15 点在位于山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室举 行的 2024 年年度股东大会（以下简称"本次股东大会"），并根据《中华 人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 及《上市公司股东大会规则》等法律法规及规范性文件和《瑞康医药股份集 团有限公司章程》（以下简称"《公司章程》"）的规定，就本次股东大会 的召集与召开程序、出席会议人员的资格和召集人的资格、审议事项以及 表决方式、表决程序、表决结果依法进行见证，并出具法律意见。 为出具本法律意见书，本所律师审查了贵公司提供的以下文件，包括： 1、贵公司的《公司章程》； 2、贵公司于 2025 年 4 月 23 日、5 月 6 日分别召开的第五届董事会第 十四次会议、第五届董事会第十六次会议决议； 3、贵公司于 2025 年 4 ...

Core Viewpoint - 瑞康医药 is actively engaging in strategic acquisitions and capital raising to enhance its position in the medical device sector and address future challenges in the healthcare industry [1][2][3] Group 1: Company Actions and Strategies - 瑞康医药 announced a share buyback plan using bank loans and its own funds, with the intention to use the repurchased shares for employee stock ownership plans or equity incentives within three years [1] - The company is acquiring 浙江衡玖医疗器械有限责任公司 to expand its footprint in the high-end medical equipment sector, specifically targeting advanced imaging systems [1] - The issuance of shares to specific investors is aligned with the company's strategic development needs and complies with relevant regulations, providing efficient funding support for operations [2] Group 2: Financial Performance - In Q1 2025, 瑞康医药 reported a main revenue of 1.757 billion yuan, a year-on-year decrease of 12.98%, and a net profit attributable to shareholders of 14.171 million yuan, down 6.58% [3] - The company's net profit excluding non-recurring items was 10.034 million yuan, reflecting a significant decline of 44.75% year-on-year [3] - The company's debt ratio stands at 64.53%, with investment income of 5.233 million yuan and financial expenses amounting to 49.171 million yuan, resulting in a gross margin of 13.85% [3] Group 3: Future Outlook - 瑞康医药 is considering entering the elderly care industry as a response to the aging population, indicating a strategic focus on addressing future healthcare needs [3]

Group 1: Share Buyback and Financing - The company plans to use repurchased shares for employee stock ownership plans or equity incentives, with unutilized shares to be canceled if not used within three years [1] - The issuance of new shares is a strategic necessity to support the company's development and complies with relevant regulations [2] Group 2: Acquisition Strategy - The acquisition of Zhejiang Hengjiu Medical Equipment Co., Ltd. aims to enhance competitiveness in high-end medical device R&D and production [2] - The acquisition aligns with the company's overall strategy to expand in the healthcare industry and does not pose risks of benefiting the actual controller at the expense of non-related shareholders [2] Group 3: Future Planning - The company is exploring suitable methods for entering the elderly care industry, addressing the impending retirement of the baby boomer generation from the 1950s and 1960s [2]

瑞康医药集团股份有限公司 证券代码：002589 证券简称：瑞康医药 公告编号：2025-031 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与投资者的互动交流，瑞康医药集团股份有限公司（以下简称 "公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司 联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 董 事 会 2025 年 5 月 14 日 关于参加2025年山东辖区上市公司投资者 1 网上集体接待日活动的公告 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司高管将在线就公司经营状况等投资者关心的问题，与投资者进行沟通与 交流，欢迎广大投资者踊跃参与！ 特此公告。 瑞康医药集团股份有限公司 ...